关键词: 肝细胞癌, 复发性肝癌, 靶向治疗, 免疫治疗

Abstract:

Targeted therapy and immunotherapy for recurrent liver cancer        MAO Ting-hui，WU Gang. Department of Hepatobiliary and Transplantation Surgery，the First Hospital of China Medical University，Shenyang 110001，China.
Corresponding author: WU gang，E-mail：cmuwgzwl@126.com
Abstract    The recurrence and metastasis rate of hepatocellular carcinoma (HCC) is high after operation，and more than 50% of HCC patients will eventually receive systemic treatment. There is a lack of systemic treatment for advanced liver cancer，so that Sorafenib is the only first-line therapeutic drug in the past ten years. Recently，positive results have been obtained in the III phase clinical trials of lenvatinib，regorafenib，cabozantinib and Ramucirumab，and anticancer effect of the immunotherapy of liver cancer shows gratifying，but there are still some shortcomings，such as low objective response rate and lack of effective clinical biomarkers. The antitumor effect of immunotherapy-based combined therapy is more satisfactory than that of single drug without more serious side effects in I/II phase clinical trials，which means immunotherapy-based combined therapy should be the future treatment strategy.

Key words: hepatocellular carcinoma（HCC）, recurrent liver cancer, targeted therapy, immunotherapy